Vizgen will continue to ship a limited number of Merscope instruments for the next several months before releasing the system to the wider U.S. market in late 2021. Participants in the summer release program include the Salk Institute; the University of California, Irvine; and Beth Israel Deaconess Medical Center.

Merscope is the first commercially available high-plex, single-cell spatial genomics platform for spatially profiling gene expression across whole tissues and resolving individual transcripts with nanometer-scale resolution. Image courtesy of Vizgen.

Merscope can perform multiplexed error-robust fluorescence in situ hybridization (Merfish) experiments, detecting spatial gene expression profiling data across whole tissues. The Merfish workflow can resolve individual transcripts with nanometer-scale resolution via combinatorial labeling, sequential imaging, and barcoding. Merfish was developed by Xiaowei Zhuang, PhD, a Howard Hughes Medical Institute investigator and David B. Arnold Jr. professor of science at Harvard University.

The instrument is flexible and amenable to a variety of sample and tissue types, according to the company. In addition to the instrument, the Merscope platform includes a custom gene panel design portal, reagents and consumables, an analytical computer, and data visualization software. The platform provides a user-friendly workflow for facilitating each step of a Merfish experiment, the company said.

Vizgen raises $37M to bring Merscope platform to market
Vizgen has closed $37 million in financing to support the commercialization and manufacturing of its Merscope platform.

Vizgen launches integrated Merscope in situ imaging platform
Vizgen has launched its Merscope platform, a multiplexed, error-robust, single-cell in situ transcriptomic imaging technology.

Vizgen debuts accelerator lab in the U.S.
Life sciences company Vizgen has established an accelerator lab in the U.S. to advance pharmaceutical research and development.